Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07406594 · ClinicalTrials.gov registry record · NA
Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer
A NA study, sponsored by University of Vermont Medical Center.
- Not yet
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT07406594 is a NA study that has not yet begun recruiting, run by University of Vermont Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT07406594, a NA study, has not yet begun recruiting, sponsored by University of Vermont Medical Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
Abemaciclib (Verzenio) is a commonly used treatment for hormone receptor-positive breast cancer, but it can cause gastrointestinal side effects such as diarrhea, which may affect quality of life and treatment tolerance. The gut microbiome, which is the collection of bacteria living in the digestive tract, may play a role in these symptoms. The purpose of this study is to examine how the gut microbiome changes during the early phase of abemaciclib treatment and how these changes relate to gastrointestinal symptoms experienced by patients. Participants will provide stool samples at multiple time points using mailed collection kits and will complete questionnaires about gastrointestinal symptoms while receiving standard-of-care abemaciclib therapy. All study procedures will be conducted remotely. Information gained from this study may help inform future supportive care strategies for breast cancer patients receiving abemaciclib.
Interventions
- DIETARY_SUPPLEMENT Placebo control
- DIETARY_SUPPLEMENT Resistant Potato Starch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2027-10 |
| Est. Completion | 2031-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07406594
The ClinicalTrials.gov registry entry for NCT07406594 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont Medical Center, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo control is the first listed.
NCT07406594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07406594 about?
NCT07406594 is a clinical study titled "Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer". Abemaciclib (Verzenio) is a commonly used treatment for hormone receptor-positive breast cancer, but it can cause gastrointestinal side effects such as diarrhea, which may affect quality of life and treatment tolerance. The gut microbiome, which is the collection of bacteria living in the digestive ...
What is the current status of trial NCT07406594?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2027-10. Estimated completion is 2031-10.
What interventions are being tested in trial NCT07406594?
The interventions under investigation include: Placebo control (DIETARY_SUPPLEMENT), Resistant Potato Starch (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07406594?
This trial is sponsored by University of Vermont Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.